A Randomized Study of Lenvatinib 18 mg Vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Marcia S BroseYury PanaseykinBhavana KondaChristelle de La FouchardiereBrett G M HughesAndrew G GianoukakisYoung Joo ParkIlia RomanovMonika K KrzyzanowskaSophie LeboulleuxTerri A BinderCorina DutcusRan XieMatthew H TaylorPublished in: The Journal of clinical endocrinology and metabolism (2021)
A starting dose of lenvatinib 18 mg/day did not demonstrate noninferiority compared with a starting dose of 24 mg/day as assessed by ORRwk24 in patients with RR-DTC. The results represent a clinically meaningful difference in ORRwk24. The safety profile was comparable, with no clinically relevant difference between arms. These results support the continued use of the approved starting dose of lenvatinib 24 mg/day in patients with RR-DTC and adjusting the dose as necessary.
Keyphrases